0001558370-17-001314.txt : 20170303 0001558370-17-001314.hdr.sgml : 20170303 20170303090540 ACCESSION NUMBER: 0001558370-17-001314 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170228 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20170303 DATE AS OF CHANGE: 20170303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Editas Medicine, Inc. CENTRAL INDEX KEY: 0001650664 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464097528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37687 FILM NUMBER: 17661613 BUSINESS ADDRESS: STREET 1: 300 THIRD STREET STREET 2: FIRST FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-401-9000 MAIL ADDRESS: STREET 1: 300 THIRD STREET STREET 2: FIRST FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 edit_currentfolio8k.htm 8-K edit_Current_Folio_8K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 28, 2017

 

 

Editas Medicine, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

001-37687

 

46-4097528

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

11 Hurley Street
Cambridge, Massachusetts

 

02141

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (617) 401-9000

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

Item 5.02.            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 28, 2017, Editas Medicine, Inc., a Delaware corporation (the “Company”), and Alexandra Glucksmann, Ph.D., Chief Operating Officer of the Company, agreed that Dr. Glucksmann’s employment with the Company will terminate effective March 31, 2017. In addition, on February 28, 2017, the Compensation Committee of the Board of Directors of the Company agreed to accelerate the vesting with respect to an aggregate of 33,969 shares of the Company’s Common Stock subject to a restricted stock award and a stock option granted to Dr. Gucksmann and to extend the exercise period under the option from three months to one year following termination of employment.  Dr. Glucksmann is entitled to receive severance benefits under the Company’s Severance Benefits Plan, consisting of twelve months’ base salary and reimbursement of Company contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act, or COBRA, for up to twelve months.   

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

EDITAS MEDICINE, INC.

 

 

 

Date:  March 3, 2017

By:

/s/ Katrine S. Bosley

 

 

Katrine S. Bosley

 

 

President and Chief Executive Officer